COMP <GO>
ESLT vs TMO // NET PROFIT MARGIN
Elbit Systems Ltd. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ESLT 5
— TMO 7
▲ NET PROFIT MARGIN LEADER: TMO
LAST: $779.68 (-3.43%) • MKT CAP: $37.55B
net-margins
6.70%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
net-margins
15.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ESLT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ESLT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 24.40% | 41.00% | -16.60 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.10% | 9.30% | +5.80 | ESLT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.8x | 30.4x | +12.40 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 1.47% | 2.40% | -0.93 | TMO | /fcf-yield <GO> |
| Operating Margin | 8.50% | 17.40% | -8.90 | TMO | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 6.70% | 15.10% | -8.40 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 3.90% | +12.40 | ESLT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.30% | 0.24% | +0.06 | ESLT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.02 | 4.50 | +0.52 | ESLT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.70% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.7 | 59.1 | +0.57 | ESLT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.94 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 59.1x | 36.3x | +22.80 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.55B | $262.22B | -$224.67B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ESLT REV | TMO REV | ESLT GROSS % | TMO GROSS % | ESLT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.94B | $44.56B | 24.4% | 44.0% | $552.8M | $6.29B |
| FY 2024 | $6.83B | $42.88B | 24.0% | 44.0% | $319.6M | $7.27B |
| FY 2023 | $5.97B | $42.86B | 44.0% | 44.0% | -$155.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ESLT // BETA 0.94
TMO // BETA 0.94